GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...

The complex sugar molecules that festoon our cells are often treated as little more than biological decoration. A new study ...

Oxetanes and other four-sided molecular rings have become increasingly common in drug design thanks to their small size and ...